News
GKOS
95.13
-1.82%
-1.76
Glaukos Announces the Release of its 2023 Sustainability Report
Glaukos Corporation has published its 2023 Sustainability Report. The report highlights the company’s continued commitment and progress on its key corporate sustainability initiatives. Glaukos is an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma.
Barchart · 3d ago
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
NASDAQ · 4d ago
Weekly Report: what happened at GKOS last week (0408-0412)?
Weekly Report · 4d ago
GLAUKOS CORP <GKOS.N>: TRUIST SECURITIES RAISES TARGET PRICE TO $120 FROM $110
Reuters · 4d ago
Needham sees BSX, CNMD, RMD beating Street, despite medtech slow down
Needham sees BSX, CNMD, RMD and Surmodics beating Street, despite medtech slow down. Needham estimates medtech sales grew less than expected in Q1, but that Boston Scientific, CONMED and ResMed should still beat the Street. The investment firm says medtech market only grew by 5.3% in the first quarter of 2024.
Seeking Alpha · 4d ago
Glaukos Price Target Raised to $100.00/Share From $85.00 by Mizuho
Dow Jones · 04/11 11:48
Glaukos Is Maintained at Neutral by Mizuho
Dow Jones · 04/11 11:48
GLAUKOS CORP <GKOS.N>: MIZUHO RAISES TARGET PRICE TO $100 FROM $85
Reuters · 04/11 11:36
Press Release: Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1
Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1 Conference Call and Webcast Scheduled for 1:30 p.m. PT. Glaukos is an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company will release first quarter 2024 financial results after the market close on Wednesday, May 1, 2024.
Dow Jones · 04/10 11:02
Validea Detailed Fundamental Analysis - GKOS
NASDAQ · 04/08 18:04
Analyst Ratings For Glaukos
Glaukos Corp is an ophthalmic medical technology company focused on the treatment of glaucoma. In the last three months, 7 analysts have published ratings on Glaukos. The company has an average 12-month price target of $109.43.
Benzinga · 04/08 16:00
Glaukos (GKOS) Hits 52-Week High: What's Driving the Stock?
NASDAQ · 04/08 14:41
Weekly Report: what happened at GKOS last week (0401-0405)?
Weekly Report · 04/08 09:23
Glaukos' (GKOS) iDose TR Receives Permanent J- Code From CMS
NASDAQ · 04/04 16:02
Glaukos Corporation (NYSE:GKOS) Not Lagging Industry On Growth Or Pricing
Glaukos Corporation's price-to-sales ratio is 14.8x compared to the Medical Equipment industry in the US. The company has a forecasted revenue growth of 22% over the next three years. Glaukos' P/S ratio is high compared to its peers but the company has grown revenues by 11% in the last year.
Simply Wall St · 04/04 12:56
Glaukos Corp: Statement of changes in beneficial ownership of securities
Press release · 04/04 01:44
Glaukos gains on permanent J-code for iDose TR
Glaukos Corporation (GKOS) gains on permanent J-code for its eye disorder therapy iDose TR. The J- code will take effect on July 1, 2024, increasing patient access to the treatment in the U.S. Glaukos says the FDA approved the injectable procedure for reducing intraocular pressure in December.
Seeking Alpha · 04/03 16:35
Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday
Signet Jewelers shares surged 9.2% to $103.80 on Wednesday. Shares of the company rose sharply after the company raised its FY25 guidance. Destiny Tech100 Inc. Shares jumped 21.4% and Ocugen shares jumped 14.2%. The Dow Jones gained over 50 points in Wednesday's session.
Benzinga · 04/03 14:31
Glaukos Price Target Maintained With a $110.00/Share by Stifel
Dow Jones · 04/03 13:00
Stifel Reiterates Buy on Glaukos, Maintains $110 Price Target
Benzinga · 04/03 12:50
More
Webull provides a variety of real-time GKOS stock news. You can receive the latest news about Glaukos Corp through multiple platforms. This information may help you make smarter investment decisions.
About GKOS
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.